Amylin analogue mechanism: satiety signalling separate from GLP-1 posts 61–90

The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.

Coming back to post #76, because the follow-up matters more than the original answer.

Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.

For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

I read post #81 twice before replying, because I had assumed the opposite.

Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.

This follows post #81 rather than contradicting it.

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.

The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.

post #85 answers the question as asked. The question underneath it is different.

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.

Coming back to post #85, because the follow-up matters more than the original answer.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

Worth separating two things that post #85 runs together.

Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.